Skip to main content

Market Overview

Perrigo: Q4 Earnings Insights



Shares of Perrigo (NYSE:PRGO) rose 0.6% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 12.26% over the past year to $0.93, which missed the estimate of $1.00.

Revenue of $1,290,000,000 declined by 2.49% from the same period last year, which missed the estimate of $1,320,000,000.


Perrigo sees FY21 adjusted EPS of $2.50-$2.70.

Details Of The Call

Date: Mar 01, 2021

Time: 08:00 AM

ET Webcast URL:

Price Action

52-week high: $62.25

Company's 52-week low was at $38.20

Price action over last quarter: down 10.73%

Company Profile

Perrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to OTC and later with strategic acquisitions. The company has a portfolio of more than 3,000 product formulations and 14,000 stock-keeping units. Most of its manufacturing and customer base reside in North America. With the most recent management change, the company announced a narrower focus on consumer wellness in conjunction with the divestiture of animal health, acquisition of Ranir Global Holdings, and plans to sell or spin off the prescription business.


Related Articles (PRGO)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at